Home » Stocks » ORGO

Organogenesis Holdings, Inc. (ORGO)

Stock Price: $3.65 USD 0.00 (0.00%)
Updated Oct 30, 2020 4:00 PM EDT - Market closed
After-hours: $3.47 -0.18 (-4.93%) Oct 30, 6:58 PM

Stock Price Chart

Key Info

Market Cap 392.22M
Revenue (ttm) 269.60M
Net Income (ttm) -37.26M
Shares Out 107.46M
EPS (ttm) -0.37
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Oct 30, 2020
Last Price $3.65
Previous Close $3.65
Change ($) 0.00
Change (%) 0.00%
Day's Open 3.68
Day's Range 3.60 - 3.77
Day's Volume 112,967
52-Week Range 2.47 - 8.34

More Stats

Market Cap 392.22M
Enterprise Value 466.78M
Earnings Date (est) Nov 9, 2020
Ex-Dividend Date n/a
Shares Outstanding 107.46M
Float 11.18M
EPS (basic) -0.37
EPS (diluted) -0.37
FCF / Share -0.47
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 404,164
Short Ratio 2.04
Short % of Float 3.62%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 1.45
PB Ratio 10.70
Revenue 269.60M
Operating Income -27.30M
Net Income -37.26M
Free Cash Flow -49.62M
Net Cash -74.56M
Net Cash / Share -0.69
Gross Margin 68.63%
Operating Margin -10.12%
Profit Margin -13.80%
FCF Margin -18.40%
ROA -8.89%
ROE -124.24%
ROIC -15.90%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 4
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

(139.73% upside)
Current: $3.65
Target: 8.75
*Average 12-month price target from 4 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Revenue Growth34.91%-2.55%43.09%-
Gross Profit18512513790.53
Operating Income-29.45-47.90-5.50-8.78
Net Income-40.45-64.83-8.39-16.99
Shares Outstanding92.8469.3263.8863.20
Earnings Per Share-0.44-0.94-0.14-0.27
Operating Cash Flow-33.53-60.64-3.49-4.87
Capital Expenditures-6.23-1.86-2.42-1.25
Free Cash Flow-39.76-62.49-5.91-6.12
Cash & Equivalents60.3721.412.36311
Total Debt10159.261020.43
Net Cash / Debt-40.24-37.86-99.98311
Book Value55.5847.04-15.325.00
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Organogenesis Holdings, Inc.
Country United States
Employees 835
CEO Gary S. Gillheeney

Stock Information

Ticker Symbol ORGO
Stock Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Unique Identifier NASDAQ: ORGO


Organogenesis Holdings, a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company's advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company's pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.